Verdiva Bio
- Health & Biotech
- London, GB
- Founded 2024
- Private
- verdivabio.com
Clinical-stage biotech developing once-weekly oral and injectable GLP-1 and amylin drugs for obesity and cardiometabolic disease, licensed from China's Sciwind.
$411MEquity raised in 2025–20262025 $411M · 2026 — · 1 equity round
$411MEquity raised, all time1 equity round on record
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 1 round · 3 sources
- Series AAmount$411MPost-money—✓ Confirmed
Investors 7
- Forbion1
- General Atlantic1
- Lilly Asia Ventures
- Logos Capital
- LYFE Capital
- OrbiMed
- RA Capital Management
Highlighted investors led at least one equity round; the number is equity rounds taken part in.
Related companies shared investors
SambaNovaAI Infra · $1.4B in 2025–2026Shared: General AtlanticAppsFlyerEnterprise · $1B in 2025–2026Shared: General AtlanticRunwayAI Apps · $623M in 2025–2026Shared: General AtlanticICEYEDefense · $520M in 2025–2026Shared: General AtlanticNerdioEnterprise · $500M in 2025–2026Shared: General AtlanticKavakConsumer · $427M in 2025–2026Shared: General Atlantic
Also in the London hub see on the globe
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. Verdiva Bio and its logo are trademarks of their owners, used here for identification only.
